All posts by medical

Immunology

Phathom Pharmaceuticals Expands Leadership Team and Announces Board Transition – Business Wire

BUFFALO GROVE, Ill.--(BUSINESS WIRE)--Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today multiple executive appointments. As previously announced as part of the Companys succession plan, Terrie Curran, former President of the Global Inflammation and Immunology (I&I) Franchise at Celgene, now joins Phathom as Chief Executive Officer. Founding CEO David Socks transitions to interim Chief Financial Officer and remains a member of the Board of Directors. In addition to Ms. Curran, also joining the Phathom leadership team are Eckhard Leifke, MD, as Chief Medical Officer; Joseph Hand, JD, as Chief Administrative Officer; and Larry Miller, JD, as General Counsel. Phathom also announced today that Asit Parikh, MD, PhD has replaced Chris Slavinsky on the Companys Board of Directors.

I am thrilled to be joining Phathom at this exciting time, as vonoprazan, our product candidate for the treatment of acid-related disorders, moves into Phase 3 clinical trials in multiple indications, said Ms. Curran. I look forward to continuing to work with David, along with our expanded leadership team, to bring this important and novel therapy to underserved patients. I am also very pleased with our ability to attract exceptionally talented and experienced leaders such as Eckhard, Joe, and Larry as we continue to build the Company.

Ms. Curran has more than 20 years of experience in the biopharmaceutical industry. She has served as President, Global Inflammation and Immunology (I&I) Franchise and as a member of the Executive Committee at Celgene Corporation since 2017. Ms. Curran joined Celgene in 2013 as the U.S. Commercial Head of the I&I Franchise and built the capabilities and recruited the teams that executed the successful launch of OTEZLA, which was sold to Amgen in November 2019 for $13.4 billion. Prior to joining Celgene, she served as Senior Vice President and General Manager, Global Womens Health at Merck & Co. She currently serves on the board of Myovant Sciences and previously served on the board of H. Lundbeck A/S. Ms. Curran holds graduate and bachelors degrees from the University of Technology, Sydney.

Dr. Leifke joins Phathom from Omeros where he served as Chief Medical Officer. Prior to Omeros, he held executive roles at Sanofi, including Global Head/Vice President of Early Project & External Opportunities - Cardiovascular and Metabolism and Global Head/Vice President of Late Stage Development - Diabetes. Dr. Leifke has built global teams at pharmaceutical companies including Bayer and Takeda and led the global development of multiple early- and late-stage small molecule and biologic drug candidates to successful marketing authorizations worldwide. Dr. Leifke holds an MD from the University of Freiburg, Germany and is board-certified in internal medicine and endocrinology.

Mr. Hand joins Phathom from Celgene, where he most recently served as Executive Vice President, Global Human Resources and Corporate Services and a member of its Executive Committee. In that capacity, he was responsible for all employee-related activities including talent development, recruiting, and compensation and benefits. He was also responsible for the management of Celgenes global facilities footprint. Prior to Celgene, he was a litigation attorney at the international law firm of Jones Day. Mr. Hand holds a BBA from the University of Notre Dame and a JD from New York University School of Law.

Mr. Miller joins Phathom as General Counsel from Cyclerion Therapeutics where he served as General Counsel and Secretary. Prior to Cyclerion, he served as Senior Vice President, General Counsel and Secretary of Blue Buffalo where he led all legal activities including those related to the $8 billion acquisition by General Mills. Mr. Miller has also served as Chief Counsel for Pfizer Consumer Healthcare, Chief Counsel for the Pfizer Established Products Business Unit, and General Counsel of Enzon Pharmaceuticals. He holds an AB from Dartmouth College and a JD from Columbia University School of Law.

In addition to the executive appointments, Dr. Parikh joins Phathoms Board of Directors as Chris Slavinsky steps down following his departure from Takeda to join Prometheus Biosciences. Dr. Parikh is currently Senior Vice President and Head of the Gastroenterology Therapeutic Area Unit at Takeda. He brings to Phathoms Board significant gastrointestinal therapeutic area experience, including the global development of Entyvio and Takedas other gastroenterology programs. Dr. Parikh earned his PhD in Biochemistry and MD from Vanderbilt University and completed his internal medicine residency at the University of Pennsylvania. He also completed subspecialty training in gastroenterology at the Massachusetts General Hospital and postdoctoral work in cancer biology at MIT.

I look forward to working with Asit and expect his deep gastroenterology drug development experience will be a tremendous asset to Phathom, said Tadataka (Tachi) Yamada, MD, Chairman of the Board at Phathom. I would also like to extend my sincere thanks to Chris for his instrumental role in shaping Phathom from its inception.

About Phathom

Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom has licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a novel potassium competitive acid blocker (P-CAB) in late-stage development for the treatment of acid-related disorders. For more information about Phathom, visit the Companys website at http://www.phathompharma.com.

Forward Looking Statements

The Company cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the companys current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding vonoprazan moving into and potential success in the Companys Phase 3 clinical trials and the effect of the Companys planned management transition. The inclusion of forward-looking statements should not be regarded as a representation by the Company that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in the Companys business, including, without limitation: the Companys ability to recruit patients for Phase 3 clinical trials; the potential for negative clinical trial results; reliance on third parties for manufacturing and certain development efforts; challenges in integrating new members of the management team and board of directors; and the need to continue to attract, integrate, retain and motivate necessary personnel to accomplish the Companys business objectives, as well as other risks described in the companys prior press releases and the Companys filings with the Securities and Exchange Commission (SEC), including under the heading Risk Factors in the Companys Registration Statement on Form S-1 and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Phathom undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Continued here:
Phathom Pharmaceuticals Expands Leadership Team and Announces Board Transition - Business Wire

Anatomy

Anatomy gym to open in Coconut Grove – The Real Deal

Rendering of Regatta Harbour

Luxury gym concept Anatomy will open in Coconut Grove next year.

Anatomy inked a lease for 14,500 square feet at Regatta Harbour, The Real Deal has learned. Treo Group is developing the mixed-use project at 3385 Pan American Drive. Anatomy will be located in ground-floor retail space on the south side of the development.

Anatomy has two other locations in the area: one near Midtown Miami at 3415 Northeast Second Avenue in Miami, and another at 1220 20th Street in Miami Beach.

Arquitectonica is designing Regatta Harbour, which spans 9.5 acres of land along the bayfront in the Grove. The project will have more than 100,000 square feet of retail and chef-driven restaurants, including Top Chef winner Jeremy Fords boat-to-table concept called Afishonado.

Anatomy will open at the project in 2020. The first phase of Regatta Harbour, a $5.5 million renovation of the former Grove Key Marina, was completed in February. It includes dry storage for more than 400 boats, new launch points and boat lifts, floating docks and a new fueling station.

The developers plan to restore and renovate old airplane hangars that were used in the early 1900s as the first Naval air station in the continental U.S. One hangar will be converted to marina storage and the other 20,000-square-foot hangar will likely become a gourmet food hall.

Lyle Stern and Sara Wolfe of Koniver Stern Group are handling the commercial leasing.

Treo secured approval for the 50-year lease, plus two options, from the Miami City Commission in 2013. Treo is currently paying the minimum $1.4 million in annual rent, but that will change once a parking garage built by the citys parking authority is completed.

Treo, led by Eduardo Garcia and Otto Boudet-Murias, financed construction with a $33 million loan from FirstBank Florida it closed on in 2018.

Regatta Harbour is across the street from Terras Grove at Grand Bay condo development and Terra and the Related Groups Park Grove project.

Visit link:
Anatomy gym to open in Coconut Grove - The Real Deal

Anatomy

How a Greys Anatomy Episode Led to an Increase in Sexual Assault Awareness – Glamour

We may be living in the age of too much content (because really, who can get to it all?!), but a new study shows that one single episode of popular television can still make a big impact on the world. Grey's Anatomy has been in our lives since it premiered on ABC in 2005, and over the past 15 seasons, fans have seen many powerful and emotional episodes. But one, in particular, from last March is proving to have a lasting effect on awareness around sexual assault.

"Silent All These Years" first aired on March 28, 2019, and featured a storyline with a patient named Abby, who Dr. Jo Karev and Dr. Teddy Altman learn has been sexually assaulted. At the time I wrote about how sensitively the show handled the issue of consent on many levels, but particularly how the doctors treated Abby as they examined her. The episode culminated in an emotional moment in which female doctors, nurses, and other hospital staff line the hallway as Abby was taken into surgery because every male face she sees reminds her of her attacker.

At the end of the show, Ellen Pompeo did a PSA about reaching out for help if they had been affected by sexual violence, and gave information about contacting the National Sexual Assault Hotline operated by the Rape, Abuse & Incest National Network, or RAINN (800-856-HOPE or via online chat hotline.rainn.org/online/). And now a new study is showing the real-life impact of the show.

Researchers at the Oklahoma State University Center for Health Sciences studied search trends on Google and Twitter for two weeks before and one week after the episode aired. They monitored terms like Rape, Abuse, and Incest National Network," RAINN, sexual assault, rape, sexual assault hotline, and tweets mentioning @RAINN. They also collected data from RAINN on call volumes in the 48 hours after the episode aired.

Engagements with the @RAINN Twitter account and tweets mentioning sexual assault hotline increased by 1,097% the day after the episode, researcher Trevor Torgerson told Reuters Health. They also found the National Sexual Assault Hotline call volume increased by 43% in the 48 hours after the episode, and the volume of searches for the term RAINN was 41% larger than expected, and search volumes for rape and sexual assault were 8% and 9% higher, respectively. In addition, the number of tweets mentioning sexual assault hotline and RAINN were 1,995% and 292% higher than usual.

An adored actor, such as Ellen Pompeo, may be able to convince someone to seek help in a way that only flashing the hotline number may not be able to," Torgerson said. "That being said, if flashing the hotline number is all that can be done, we would agree there is a benefit to it.

Whatever the factors, it's incredible to see the impact that one episode of television (in this case, Grey's Anatomy) can have on the world.

Read more:
How a Greys Anatomy Episode Led to an Increase in Sexual Assault Awareness - Glamour

Anatomy

Anatomy of a Play: Josh Jacobs 35-yard scamper – Silver And Black Pride

Josh Jacobs was one of the few bright spots this past weekend for the Raiders. Sprinkled throughout their epic drubbing at the hands of division rivals Kansas City Chiefs, the Raiders got some quality plays from the rookie RB.

The biggest run of the night was a 35-yard sprint around the offensive left side that gave the Raiders a chance to score at the end of the half. But how did the Raiders manage to get such a wide open running lane for Jacobs?

Lets go back to the very first play from scrimmage from the Raiders offense. They lined up in 11 personnel (1 Back, 1 TE) and ran a play-action boot targeting Darren Waller in the flat. Waller is lined up off the line of scrimmage next to the LT and comes across the formation.

The next player to look at is Chiefs Safety Daniel Sorensen. Sorenson comes on a blitz and is able to disrupt this play by getting in Carrs face.

Fast forward to Jacobs 35-yard run at the end of the half. A few things are the same:

Sorensen thinks he recognizes the play and abandons his gap in the run game in hopes that he can make a big play on what appears to be a bootleg. Only this time the Raiders are actually running the ball and the void Sorensen leaves allows Jacobs to accelerate into the second level.

Of course, there werent enough examples of plays like this coming to fruition for the Raiders. Its telling that a non-scoring play was their best play of the game. The last several weeks the offense has taken a step back. Theyll need to create more explosive offense if they have a chance of righting the ship this week against the Titans.

View original post here:
Anatomy of a Play: Josh Jacobs 35-yard scamper - Silver And Black Pride

Anatomy

Anatomy of a Sculpture – Art and Performance Winter 2019 – TheStranger.com

Timothy Kinney

MORE THAN 10 FEET TALL

Measuring nearly 10.5 feet tall and weighing approximately 1,200 pounds, The Weaver's Welcome greets visitors at the new Burke Museum with its palms facing up and out, a traditional Coast Salish gesture of welcome.

Timothy Kinney

THE MATERIALS

While traditional welcome figures are made of wood, The Weaver's Welcome is made of cast glass. The sculpture is composed of three separate piecesthe head and the left and right sides of the bodyheld together by fabricated steel.

THE ARTISTS

The sculpture is a collaboration between the artists Brian Perry (Port Gamble S'Klallam), Anthony Jones Sr. (Port Gamble S'Klallam), Preston Singletary (Tlingit), and David Franklin. The artists sought to pay tribute to the Coast Salish people whose land Seattle (and the Burke Museum) sits on.

Timothy Kinney

THE HEAD

The relief work on the corona reflects a Northern Salish Sea design style, commonly found on spindle whorls used in weaving on the southern coast of British Columbia. The face of the welcomer is inspired by Salish and Makah style facial sculpture and wears a typical Salish woven hat decorated with a common pattern in local Native weaving.

THE BODY

Elements of basketry served as a major source of inspiration. The triangles that run down the sides are in the design style of communities from the Southern Salish Sea down to the Columbia River. Up close, viewers can see ridges in the glass, made to evoke the texture of baskets.

Timothy Kinney

THE BASE

The steel chest the glass sculpture sits on is inspired by a small Quinault bentwood box in the Burke's permanent collection, the white dots representing beaded inlays in the wood. Those beads are an example of some of the first glass art in our region. One side of the chest is the moon over water, while the other side is the sun and mountains.

THE BLUE

The translucent blue color of the sculpture represents water. In the newly reopened Burke Museum's window-filled Grand Atrium, The Weaver's Welcome is situated near the staircase, where the sunlight can pass through the blue glass, seemingly illuminating the figure from within.

THE NEW BURKE

The Burke Museum reopened this past October in a new Tom Kundigdesigned building at the University of Washington. In addition to historical objects like baskets and carvings, the natural history museum's collection includes things like leaf fossils and dinosaur bones.

Visit link:
Anatomy of a Sculpture - Art and Performance Winter 2019 - TheStranger.com

Anatomy

Grey’s Anatomy Season 16: Release Date, Cast, Plot And Other Major Details – The Digital Weekly

Hey, fans of Greys Anatomy, here is good news for you that Greys Anatomy is returning for two more seasons. In May, ABC stated that Shonda Rhimess classic medical drama is coming back for two more seasons, giving the lasting primetime medical drama in TV past time. Best of all: The wild world of Grey Sloan returns with season 16 September 26.

TheGreys Anatomy Season 16 opening is Thursday, September 26 at 8 pm ET/7 pm CT on ABC, with following episodes broadcasting on Thursdays on the system as part of their TGIT list.

The 16th Season is anticipated to have around 25 episodes, taking devotees to the middle time of May 2020. Episodes will be free to stream online on Hulu and the ABC website and app after broadcasting. The last 15 seasons are streaming on Netflix for those who desire to get their beloved epic episodes.

Here we are going to tell you the expected to cast to come back for Season 16, Meredith Grey would be playing by Ellen Pompeo, Alex Karev would perform by Justin Chambers, Miranda Bailey would be presenting by Chandra Wilson.

More cast including James Pickens Jr. would play as Richard Webber, Kevin McKidd as Owen Hunt, Kim Raver as Teddy Altman, Camilla Luddington as Jo Karev, Amelia Shepherd would play by Caterina Scorsone, Maggie Pierce would present by Kelly McCreary, Andrew DeLuca would paly by Giacomo Gianniotti.

We could see some great changes in the imminent season after the episodes of the last denouement which noticed Meredith, Richard, and Alex taking the fall for security deception. Season 16 chooses times from where it has concluded, Vernoff said, with the band still ignited and Jackson still wanting.

Merediths new character creates difficulties between her and DeLuca according to Vernoff, who stated: They have learned to operate the difficulties of a new relationship in the wake of Meredith having been shot and having broken the rule There are stressors on their very new relationship appearing from the consequences of those decisions previous season.

Further, the triple-firing will also have consequences for the rest of the crew of Grey Sloan. As Levi star Jake Borelli said that Its going to be difficult because a lot of the senior doctors have now dropped their works and he thought that its going to hit everybody in a strange direction. Thats where we choose. We started to understand how one resolution concerns all of these doctors individually.

He thought we were still getting how it changes Levi. Many of these people hes developing for the previous some of the years and he was sawed in a little unusual light maybe. So, were still concluding, but he thought it would be interesting.

More here:
Grey's Anatomy Season 16: Release Date, Cast, Plot And Other Major Details - The Digital Weekly

Biochemistry

Global Biochemistry Analyzers Market Key players and Growth Analysis Outlook up to 2019 to 2028 – Tech News Today

The Biochemistry Analyzers Market 2019-2028 Analytical Reporthasrecently published byMarketresearch.bizto its massive repository. The research report has been summarized with informative and technical details of the dynamics of the market. It has been compiled by using some significant research methodologies such as primary and secondary research techniques.

The Biochemistry Analyzers report also elaborates on the factors which are fueling or hampering the growth of the market. It gives more focus on recent trends and technologies which have been adopted by top-level industries are elaborated to get proper directions for the businesses and boosting the performance of the companies.

The Biochemistry Analyzers report includes a comprehensive overview of the global Biochemistry Analyzers market, which also sheds light on the scope of the product. The analysts have categorized the market into different segments on the basis of some significant market segments such as type, modality, end user, and region. After a careful analysis of the market as per these categories, the analysts have revealed the market and production shares of several segments for the review period.

Fill Out Details to Receive Free Sample Report Copy Here @https://marketresearch.biz/report/biochemistry-analyzers-market/request-sample

Prominent Top Key Vendors of Biochemistry Analyzers Report:-Abbott Laboratories, Danaher Corporation, Hoffman-La Roche Ltd, Meril, Siemens AG, Hologic Inc, Thermo Fisher Scientific Inc, Randox Laboratories Ltd, Beckman Coulter Inc, Horiba Medical

The geographical segmentation of the global Biochemistry Analyzers market allows users of the report to formulate a multilevel perspective of the market in terms of regional prominence and global expansion plans. Additionally, it throws light on leading industry key players across the global regions such as North America, Latin America, Asia-Pacific, Europe, The Middle East, and Africa. Different internal and external factors have been mentioned, which are responsible for fueling or restraining the progress of the companies. Informative information regarding the challenges faced by the industries and approaches adopted by them to overcome those threats has been included.

Geographical Segmentation:-

1.North America(United States, Canada)

2.Europe(Germany, Spain, France, UK, Russia, and Italy)

3.Asia-Pacific(China, Japan, India, Australia, and South Korea)

4.Latin America(Brazil, Mexico, etc.)

5.The Middle East and Africa(GCC and South Africa)

Biochemistry Analyzers Market Segmentation:-

Global biochemistry analyzers market segmentation, by type:

Semi-AutomaticFully AutomaticGlobal biochemistry analyzers market segmentation, by modality:

Bench TopFloor StandingGlobal biochemistry analyzers market segmentation, by end user:

HospitalsDiagnostics CentersAcademic Research InstitutesContract Research OrganizationsPharmaceutical and Biotechnology Companies

If you have any special requirements, please let us know and we will offer you the report as per your requirements.

Ask our Industry Experts @https://marketresearch.biz/report/biochemistry-analyzers-market/#inquiry

The Key Points of this Biochemistry Analyzers Market Report are:

1. To survey and forecast the market size share of Biochemistry Analyzers, in terms of value and volume.

2. Provide detailed information concerning the Biochemistry Analyzers major factors (opportunities, drivers, restraints, and industry-specific challenges) influencing the growth of Biochemistry Analyzers market.

3. To study the future outlook and prospects for the Biochemistry Analyzers market with Marketing Price (Price and Margin, Factors of Price Change, Manufacturers Gross Margin Analysis)

4. To analyze the global key regions Biochemistry Analyzers market potential and advantage, opportunity and challenge, restraints and risks.

5. Detail Profile of the dominant players and Biochemistry Analyzers comprehensively analyses their market status in terms of ranking and core capability along with in-depth the Biochemistry Analyzers competitive landscape for the market leaders.

6. Study competitive developments like partnerships and joint ventures, Biochemistry Analyzers new product developments, expansions and research and development of Biochemistry Analyzers market.

Finally, it focuses on the beneficial opportunities for growth, which promotes a way of turning a business idea into the venture. In addition to this, it gives a detailed description of top driving factors such as Biochemistry Analyzers Market for the studies. Restraints are also provided to study the risk factors in front of businesses.

ContactUs:

Mr. Benni Johnson

MarketResearch.Biz (Powered By Prudour Pvt. Ltd.)

420 Lexington Avenue, Suite 300, New York City, NY 10170, United States

Tel: +1 347 826 1876

Email:inquiry@marketresearch.biz

Read the original:
Global Biochemistry Analyzers Market Key players and Growth Analysis Outlook up to 2019 to 2028 - Tech News Today

Biochemistry

Global C-Reactive Protein Test Market Outlook to 2026 ORTHO CLINICAL DIAGNOSTICS(J&J), Leadman Biochemistry, BioSino, KEHUA GROUP, ABBOTT -…

An Up to Date Report on C-Reactive Protein Test Market size | Industry Segment by Applications, by Type, Regional Outlook, Market Demand, Latest Trends, C-Reactive Protein Test Industry Share & Revenue by Manufacturers, Company Profiles, Growth Forecasts 2019-2026. Analyzes current Market size and upcoming 6 years growth of this industry.

A comprehensive analysis of the C-Reactive Protein Test Market is presented in this document, along with a brief overview of the segments in the industry. The study presents a feasible estimate of the current Market scenario, including the C-Reactive Protein Test Market size with regards to the volume and remuneration. The report is a collection of significant data related to the competitive landscape of the industry. It also contains data with regards to several regions that have successfully established its position in the C-Reactive Protein Test Market.

Key Players of C-Reactive Protein Test Market Report are:

ORTHO CLINICAL DIAGNOSTICS(J&J)Leadman BiochemistryBioSinoKEHUA GROUPABBOTTBoditechKANTO CHEMICALRoche DiagnosticsFUJIFILM CorporationBEIJING STRONG BIOTECHNOLOGIESGetein BiotechARLINGTON SCIENTIFICSPINREACTWondfoNingbo C-Reactive Protein test(CRP)systemSIEMENS HEALTHCARE DIAGNOSTICSPRODIA DIAGNOSTICSWako Pure ChemicalAUDITHORIBA ABXRANDOX LABORATORIESBECKMAN COULTER

Request For Free C-Reactive Protein Test Sample Report (Kindly Use Your Bussiness/Corporate Email Id to Get Priority) https://www.reportspedia.com/report/life-sciences/global-c-reactive-protein-test-market-report-2019,-competitive-landscape,-trends-and-opportunities/25643 #request_sample

A Glimpse over the highlights of the report:

The study offers synopsis of product scope of the C-Reactive Protein Test Market.

Information about the production volume and the price trends are provided in the report.

The study also offers the Market share gained by each product type in the C-Reactive Protein Test Market, along with the production growth.

Data related to the C-Reactive Protein Test Industry application spectrum is provided, and the application terrain divided into Residential and Commercial.

The report also encompasses detailed information of the Market share obtained by every application along with the projected growth rate and product consumption of every application.

Data related to Market industry concentration rate with respect to the raw materials is present in the report.

Information about the relevant price along with data related to sales together with the projected expansion trends for the C-Reactive Protein Test Market is revealed in the report.

The Market study report has been analyzed thoroughly with regards to the Marketing strategies that consist of several Marketing channels which producers implement to endorse their products.

Data with respect to Marketing channel development trends is provided in the report.

Repot Scope:

Global C-Reactive Protein Test Market Segmentation By Type and Application:

Global C-Reactive Protein Test Market Segmentation By Type

Type 1Type 2Type 3

Global C-Reactive Protein Test Market Segmentation By Application:

Application 1Application 2Application 3

C-Reactive Protein Test Market Inquiry Here For Detail Report @ https://www.reportspedia.com/report/life-sciences/global-c-reactive-protein-test-market-report-2019,-competitive-landscape,-trends-and-opportunities/25643 #inquiry_before_buying

Providing a thorough outline of the competitive and regional spheres of the C-Reactive Protein Test Market:

An important evaluation of the competitive landscape of this business is provided in the report.

Crucial data related to the Market share accumulated by each company along with facts pertaining to the sales area have been provided in the report.

The study offers a thorough assessment of the products manufactured by the firms, specifications, including their application frame of reference.

Information pertaining a basic outline, profit margins, price prototypes etc. of the companies participating in the C-Reactive Protein Test

Details related to every regions Market share along with the growth opportunities for each region is inculcated in the report.

The projected growth rate which every region is expected to register over the predicted time period is mentioned in the study.

Table Of Content

Chapter 1 :Definition, Specifications and Classification of C-Reactive Protein Test , Applications of C-Reactive Protein Test , Market Segment by Regions;

Chapter 2 :Manufacturing Cost Structure, Raw Material and Suppliers, Manufacturing Process, Industry Chain Structure;

Chapter 3 :Technical Data and Manufacturing Plants Analysis of C-Reactive Protein Test , Capacity and Commercial Production Date, Manufacturing Plants Distribution, R&D Status and Technology Source, Raw Materials Sources Analysis;

Chapter 4 :Overall Market Analysis, Capacity Analysis (Company Segment), Sales Analysis (Company Segment), Sales Price Analysis (Company Segment);

Chapter 5-6: Regional Market Analysis that includes North America, Europe, Asia-Pacific, South America, Middle East & Africa, C-Reactive Protein Test Segment Market Analysis (by Type);

Chapter 7-8 :The C-Reactive Protein Test Segment Market Analysis (by Application) Major Manufacturers Analysis of C-Reactive Protein Test ;

Chapter 9 :Market Trend Analysis, Regional Market Trend, Market Trend by Product Type, Market Trend by Application;

Chapter 10 :Regional Marketing Type Analysis, International Trade Type Analysis, Supply Chain Analysis;

Chapter 11 :The Consumers Analysis of Global C-Reactive Protein Test ;

Chapter 1 2 : C-Reactive Protein Test sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source.,

Chapter 13,14 & 15 : C-Reactive Protein Test Research Findings and Conclusion, Appendix, methodology and data source;

Explore Full C-Reactive Protein Test Report With Detailed TOC Here @ https://www.reportspedia.com/report/life-sciences/global-c-reactive-protein-test-market-report-2019,-competitive-landscape,-trends-and-opportunities/25643 #table_of_contents

Contact: Global Marketers.Biz

Mr. Alex White Email: [emailprotected]

Phone number: +1(617)2753012

Website: https://www.globalmarketers.biz/

Read the original here:
Global C-Reactive Protein Test Market Outlook to 2026 ORTHO CLINICAL DIAGNOSTICS(J&J), Leadman Biochemistry, BioSino, KEHUA GROUP, ABBOTT -...

Embryology

Story of a 15-year old scientist: How it all began – EuroScientist

Children and young adults these days have awide range of possibilities how to spend their leisure time. Some of us like to watch movies, some of us enjoy playing aflute and some of us prefer to go laboratories, put on a white coat and carry out an experiment. Zuzana Hudov, a15-year old student from Slovakia, fell into the category of teenagers who preferred going to labs and make experiments. Even though this is just onestory it once may be astory of hundreds of young aspiring students.

As alittle child Zuzanawas not much different from all the other kids in the kindergarten. Shewas playful, energetic and endlessly curious about the world surrounding her. However, curiosity diverted from the behaviour of her classmates. Most of the kids liked to explore the outside world, yet Zuzanawas more fascinated about the things that could not be understood by just looking at them. Shewould spend hours and hours browsing through an old Encyclopedia, looking at the pictures of human body, homogenesis phases and even insect behaviour. Her restless mind caused her agreat deal of problems in kindergarten since sheoften refused to go to bed during the afternoon sleep-time and, often, she would even take abook from the small kindergarten library and read it, hidden under the duvet, while other kids were sleeping. When Zuzana was five, her mother realised that the kindergarten was noplace for her daugther, and therefore, with the approval of experts, Zuzana was admitted to primary school ayear earlier than regular . That was where the real journey started, says Zuzana.

The competitive atmosphere of school brought Zuzanas ambitions and her desire to thrive to life. Even though shewas more than ayear younger than her classmates, she always perfomed very well and was one of the best pupils in her class. Although Zuzanastill preferred to read books, shefelt aresponsibility for the community and mediated with teachers and pupils about potential improvements to make; therefore she was electedclass representative.

Until the age of eleven her hobbies were pretty general: reading, playing the piano and dancing. Zuzanas interests changed when she was in sixth grade, as at that time, biology and chemistry classes were added to school curriculum. Zuzana was fascinated by the two new subjects and used to spend several hours each day to read popular science books and magazines. At the age of twelve sheperformed her first study about human body mass index (BMI) and obesity and took part in a local competition.

Due to her ambition and success in and outside school, she got the chance to study at GBAS Suany, aprestigious Slovak bilingual grammar school, where she started at the age of thirteen, and joined classes with classmates 3 years older than her.

During the biology classes, especially on the topics of neuroscience and genetics, Zuzana realised that although her desire for more knowledge was being fulfilled, her ambitions to do her own investigations and actuallycontribute to science were not satisfied. While looking for opportunities to collaborate with reasearch labs, she discovered that in many Western countries it is not uncommon for youngstudents to doscientific internships. She started contacting research institutions in Slovakia, but never was selected because of her young age. Consequently she started to applyoutside her home country and was eventually accepted as a summer intern at Masaryk University in Brno, Czech Republic at the Department of Histology and Embryology.

The laboratories that gave Zuzana this opportunity was lead by Mgr. Da Bohaiakov, Ph.D. and focused on neurogenesis research. The project she worked on was the immunofluorescent analysis of in vitro neural rosette formation from induced pluripotent stem cells (iPSCs). The aim of her research was to analyse the markers of neural rosette formation, which is a2D in vitro model of human neurogenesis. During the neurulation phase of embryogenesis there are many things than may go wrong, which can lead to neural tube defects (NTDs), such as spina bifida. NTDs are very dangerous and cause alot of pain and suffering in an individuals life. However, these days we are not only unable to treat these disorders, but we are not even able to observe the neurulation process non-invasively. That is why scientists are trying to developwith the in vitro solutions, which neural rosettes might potentially be.

Zuzanas first laboratory internship marked some new beginnings in her life such as the her first successfull research project, and afirst scientific work that won the 3rd place at the national Stredokolsk Odborn innos (High School Scientific Activity). At the age of 15 shewas the youngest participant in history.

The success of her first project was the incentive for Zuzanato participate in more scientific activities; therefore during the following term she launched abiology club at her school, took part in an international DNA essay contest where she finished among the top ten participants and carried out more work in a laboratory and completed one more internship.

In spite of all her success Zuzana still feels the responsibility for her community and she thinks that if shecould achieve all of this, why not any other student in the world? This is the reason why she decided to publish her story

Iam certainly no better than any other child, she says, yet Iwas lucky, Ihad an idea and enough passion not to give up, even though the circumstances were against me.

Zuzana hopes that her story can motivate her fellow pupils and she urges parents to foster the curiosity and ideas of their children. Additionally she wants to send the message that is importnat to look outside your own surrounding and use the possibilities Europe of today gives to everyone.

By Zuzana Hudacova

Featured image credit: Zuzana Hudov

Like Loading...

Related Posts

Continue reading here:
Story of a 15-year old scientist: How it all began - EuroScientist

Embryology

Systemic Injection of Thalidomide Prevent and Attenuate Neuropathic Pa | JPR – Dove Medical Press

Hao Xu,1,2,* Sha-Jie Dang,3,4,* Yuan-Yuan Cui,1 Zhen-Yu Wu,1 Jun-Feng Zhang,2 Xiao-Peng Mei,5 Yu-Peng Feng,1 Yun-Qing Li1

1Department of Anatomy, Histology and Embryology, K.K. Leung Brain Research Centre, The Fourth Military Medical University, Xian, Shaan Xi, Peoples Republic of China; 2Institution of Basic Medical Science, Xian Medical University, Xian, Shaan Xi, Peoples Republic of China; 3Department of Anesthesiology, Shaanxi Provincial Cancer Hospital, Xian, Shaan Xi, Peoples Republic of China; 4The Key Laboratory of Biomedical Information Engineering of the Ministry of Education, School of Life Science and Technology, Xian Jiaotong University, Xian, Shaan Xi, Peoples Republic of China; 5Department of Anesthesiology, The First Affiliated Hospital of Xian Jiaotong University, Xian, Shaan Xi, Peoples Republic of China

*These authors contributed equally to this work

Correspondence: Yun-Qing Li; Yu-Peng FengDepartment of Anatomy, Histology and Embryology, K.K. Leung Brain Research Centre, The Fourth Military Medical University, Xian, Shaan Xi, Peoples Republic of ChinaEmail deptanat@fmmu.edu.cn; fengyp@fmmu.edu.cn

Background and objective: Thalidomide (Tha) has been shown to exert immunomodulatory and anti-inflammatory properties. Whether Tha can alleviate spinal nerve ligation (SNL)-induced neuropathic pain (NP) is still unclear. This study aimed to investigate the therapeutic effect of Tha on the SNL-induced NP and further explore the potential analgesic mechanisms of Tha.Methods: The effects of Tha on SNL-induced mechanical allodynia were assessed by pain behavioral testing. The expressions of the astrocyte marker glial fibrillary acidic protein (GFAP) and the microglia marker Iba1 in the spinal dorsal horn were evaluated by immunofluorescence histochemistry. Protein expressions of the tumor necrosis factor alpha (TNF-) in the spinal dorsal horn were tested by Western blot assay. Data were analyzed using one-way ANOVA or two-way ANOVA.Results: By the pretreatment with a single intraperitoneal injection, the PWMT in SNL+Tha group was significantly increased from day 1 to day 2 after SNL (P < 0.05 compared with SNL+Veh group). By the posttreatment with a single intraperitoneal injection, the PWMT in SNL+Tha group was also significantly increased from day 3 to day 4 after SNL (P < 0.05 compared with SNL+Veh group). By the posttreatment with multiple intraperitoneal injection, both the PWMT and the PWTL in SNL+Tha group were similarly significantly increased from day 3 to day 14 after SNL (P < 0.05 compared with SNL+Veh group). Furthermore, the GFAP and Iba1 expressions and TNF- levels of the ipsilateral spinal dorsal horn in SNL+Tha group were significantly weaker from day 3 to day 14 after SNL than those in SNL+Veh group (P < 0.05).Conclusion: Tha can significantly alleviate NP induced by SNL. The analgesic mechanism may be related to inhibition of astrocyte and microglia activation as well as down-regulation of TNF- levels in the spinal dorsal horn.

Keywords: Tha, neuropathic pain, Glia, TNF-, spinal nerve ligation

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

See original here:
Systemic Injection of Thalidomide Prevent and Attenuate Neuropathic Pa | JPR - Dove Medical Press